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PERSPECTIVES IN CLINICAL NEPHROLOGY
Chronic renal transplant loss
Ever since the inception of kidney transplant programs the
short-term patient and graft survival results have improved pro-
gressively, principally because of better management of acute
rejection episodes and decreased mortality from infectious com-
plications. However, the rate of annual graft attrition after the
first post-transplant year has virtually remained unchanged [1, 2].
About half to three quarters of the late graft losses are explained
by patient death with a functioning transplant, mainly as a result
of cardiovascular causes, while chronic rejection accounts for 50
to 80% of graft failures in surviving recipients. The estimated graft
loss from chronic rejection varies between 4 and 40% in the initial
five post-transplant years [3].
Recent clinical [3] and experimental [4] studies have shown that
acute rejection episodes are the most important risk factor for the
development of chronic rejection, but their connection is currently
unknown. Although immunological or "antigen-dependent" mecha-
nisms are central in graft rejection, there is increasing evidence to
support the hypothesis that non-immunological or "antigen-
independent" mechanisms play a role in the progressive deterio-
ration of structure and function late after transplantation. The
importance of each of these components will be discussed follow-
ing the description of the manifestations and risk factors of
chronic rejection.
Clinical and histopathological manifestations of
chronic rejection
Chronic rejection is clinically characterized by a slowly progres-
sive decline in glomerular filtration rate, usually in conjunction
with proteinuria and arterial hypertension, after the initial three
or six post-transplant months [5, 61. Contrary to the graft dysfunc-
tion of most acute rejection episodes, chronic rejection is gener-
ally felt not to respond to increased amounts of steroids or
conventional antibody treatments [7, 8]. Although up to three
quarters of late acute rejection episodes show a favorable re-
sponse to high doses of corticosteroids, deterioration of function
in the absence of acute rejection is generally not treated [9].
Although limited success has been reported in patients who
develop chronic rejection while they are on prednisone and
azathioprine from switching them to cyclosporine A [101, virtually
all patients are presently receiving cyclosporine A, and this is
therefore not a realistic option for most patients. The histopathol-
ogy of chronic rejection shows mild or moderate tissue infiltration
with T cells and macrophages, as is the case in acute rejection and
in grafts with no apparent dysfunction [11]. Chronic rejection is
furthermore characterized by variable structural lesions of the
vessels, the glomeruli and the tubulointerstitial compartment.
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One study found that the interstitial infiltrate contains higher
numbers of plasma cells compared with acute rejection or non-
transplant interstitial renal disease [12]. Immune-cytochemistry of
rat renal transplants with chronic rejection have drawn attention
to an unique population of CD45RC-positive cells in the graft
interstitium [13]. CD45RC is one of the restricted epitopes of the
CD45 Leukocyte Common antigen and is expressed on all B cells
and most T cells, but as most of the graft invading CD45RC-
positive cells were negative for lymphocyte or monocyte markers,
it was postulated that these cells represent a CD8-negative
subpopulation of natural killer cells. We found a novel population
of macrophage-derived multinucleated giant cells in the intersti-
tium of rat transplants with chronic rejection [14]. It is presently
not known whether these cell types are truly specific for chronic
rejection and whether such cell types are also present in human
transplants with chronic rejection. Virtually all long-surviving
grafts with dysfunction have variable degrees of interstitial fibrosis
and tubular atrophy.
The vascular changes of chronic rejection are characterized by
mostly concentric thickening of the intima that result from
myo-fibroblast and fibroblast proliferation, deposition of extracel-
lular matrix material, and foam cell infiltration. The lesion may be
preceded by subendothelial accumulation of macrophages and
lymphocytes [15]. The vascular changes affect large parts of the
arterial tree, including the smaller vessels that are normally not
affected by atherosclerosis. The peritubular capillaries may show
thickening and multilayering of the basement membrane [16]
which may be specific for chronic rejection.
The glomeruli show a variety of abnormalities, including wrin-
kling and collapse of the glomerular tuft [17], glomerular hyper-
trophy [18], mesangial matrix expansion with partial or complete
collapse of the tuft, or focal glomeruloscierosis [19, 20]. Ham-
burger, Crosnier and Dormont were the first to describe rejection
glomerulonephritis [21], a lesion characteristic for chronic rejec-
tion, that has also been named rejection nephropathy [221,
transplant glomerular disease [23, 24], rejection transplant gb-
merulopathy [25], transplant glomerulopathy [26], or albograft
glomerulopathy [27]. The early lesions of transplant glomerulopa-
thy are characterized by enlargement of the glomeruli and gb-
merular hypercellularity with swelling of endothelial and mesang-
ial cells, mesangiolysis and infiltration of the mesangial areas with
mononuclear cells with fine bundels of PAS positive material
ramifying among the cells. Electron microscopy shows increased
rough endoplasmatic reticulum in endothelial and mesangial cells.
There is widening of subendothelial zones by electron lucent
material and interposition of mesangial matrix and cells, giving a
double contour appearance to most capillary walls. Immunofiuo-
rescence shows in most cases unspecific segmental deposits of 1gM
and fibrin, sometimes associated with trace amounts of C3, but
some cases have been described with linear deposits of IgG along
the glomerular basement membrane (GBM) or with small periph-
eral granular deposits of IgG or IgA [28]. The late picture of
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transplant glomerulopathy consists of enlarged glomeruli with
widespread reduplication of the GBM, resembling membranopro-
liferative glomerulonephritis [28], There is in later stages mild
hypercellularity and many glomeruli show a spongy appearance of
expanded mesangial areas containing swollen mesangial cells
embedded in matrix material. Slight or moderate epithelial cell
proliferation may be present, typically near adhesions between the
capillary tuft and Bowman's capsule. Electron microscopy may
furthermore show abnormal structures in the basement mem-
brane, between the basement membrane and the endothelium or
epithelium, and in the mesangial matrix [23, 29]. Immune histo-
chemistry with antibodies against extracellular matrix proteins has
shown peripheral glomerular expansion of collagen type IV and
fibronectin [30]. Transplant glomerulopathy is found in 7% of
biopsy specimens, representing 23% of all glomerular lesions
present in renal allografts [28] and is almost always associated
with obliterative vascular lesions [31].
Any of above histologic features in combination with impaired
function or proteinuria is consistent with chronic rejection after
exclusion of obvious other causes [6]. However, prospective
biopsy studies of transplants with normal or slightly increased
serum creatinine levels in the initial two years have shown that up
to 2/3 of grafts have some degree of interstitial fibrosis and tubular
atrophy and that more than 1/3 have some degree of glomerular
sclerosis and intimal proliferation. Although the extent of the
lesions is usually mild in the absence of clinical dysfunction [32,
33], the etiology of the lesions remains to be established.
Risk factors of chronic rejection
Several clinical factors are associated with late allograft failure,
as reviewed recently [34]. HLA identical sibling transplants in the
UNOS Registry have a half-life, the time it takes for 50% of
transplants that function at one year to fail, of more than 20 years
compared with less than 10 years in one haplotype mismatched,
sibling transplants and seven to eight years in completely mis-
matched cadaveric donor transplants [35]. These data suggest that
the degree of HLA matching has an important effect on long-term
graft survival. However, living-related donors usually have short
ischemia times and are, for the most part, either HLA-identical or
mismatched for a single haplotype. The Eurotransplant data show
that matching for both HLA class I and II antigens has a strongly
beneficial effect on the long-term graft survival: zero mismatched
cadaveric transplants have a 79% five year survival and a half-life
of 13.2 years compared with 51% and 7.8 years, respectively, in
completely mismatched combinations [36]; similar data have been
reported by the Collaborative Transplant Study Group [37]. It is
of interest that the UNOS data show only a long-term matching
effect for HLA class I but not class II antigens [38].
HLA matched and mismatched combinations experience the
same degree of early graft loss when acute rejection episodes
occur but there is a pronounced split in survival rates beyond the
first few months between matched and mismatched combinations
whose grafts survived the early rejection episodes, with an obvious
acceleration in graft loss among the mismatched group [39]. This
suggests that if early rejection episodes initiate late allograft loss,
its development may be dependent on HLA incompatibilities.
Furthermore, panel-reactive antibody status has no effect on early
graft outcome in HLA-identical transplants but high panel-
reactivity is associated with a decline in half-life in both matched
and unmatched recipients, suggesting that previous allosensitiza-
tion affects long-term outcome, irrespective of the degree of
matching [39].
More important than matching per se is whether tissue incom-
patibilities lead to rejection episodes [2, 39—41]. One study
showed that the average half-life decreases from 12.8 2 years
for grafts with no rejection episodes to six years or less for grafts
with multiple acute rejection episodes [41]. Although not all late
graft losses are explained by chronic rejection, multivariate anal-
ysis have shown that acute rejection episodes are the strongest risk
factor for the development of biopsy-proven chronic rejection [3].
However, a recently published study from Finland found no
correlation between acute and chronic rejection [42]. The authors
attributed this lack of correlation to the very low incidence of
acute rejection episodes which were usually mild in their partic-
ular patient population.
The possibility that late graft dysfunction or chronic rejection
emerges from inadequate immunosuppression because of con-
cerns of cyclosporine A-mediated nephrotoxic side effects [43] or
patient non-compliance [44] has been raised but needs further
study. Additional factors associated with late allograft loss include
pretransplant hyperlipidemia [45], long cold ischemia times [46],
delayed graft function [47, 48], post-transplant infections [3],
donor age [49, 50], female gender or race of the donor [49], and
recipient obesity [51]. Studies of cardiac transplant patients have
furthermore shown a correlation between post-transplant eyto-
megalovirus (CMV) infection and the development of graft
atherosclerosis [52]. Although CMV infections in renal transplant
patients have been associated with a specific glomerular lesion
postulated to evolve into transplant glomerulopathy [53, 54], later
studies have failed to confirm this relationship [55].
Hypothesis to explain the immunological or "antigen-
dependent" basis of chronic rejection
As rejection is defined as the clinical and histopathological
expression of an allogeneic immune response of the recipient
against incompatible transplantation antigens of the graft, it is
essential to define the immunological basis of chronic rejection.
CD4-positive T lymphocytes play a central role in the regulation
of the immune response as they interact with antigen presenting
cells, precursor cytotoxic T cells, maerophages, and B cells to
coordinate the response. Much of their function is controlled by
cytokines, small protein molecules whose expression and secretion
is induced as a result of antigen-stimulated cell activation. Long-
term clones of murine CD4-positive T cells tend to produce either
interleukin-2 (IL-2), interferon gamma (IFN-'y) and tumor necro-
sis factor beta (TNF-/3), or IL-4, IL-5, IL-6, IL-b, and IL-13 as
their unique cytokine products [56—58]. The former clones have
been designated as being of the T helper 1 (TH1) type, and the
latter, the TH2 type. The TH1 clones, through their production of
IFN-y and TNF-j3 are well suited to induce macrophage-mediated
delayed-type hypersensitivity reactions and cytotoxic T cell activity
while the T2 clones make products that are well adapted to act
in helping B cells develop into antibody-producing cells [57]. The
cytokines play a dual role in the differentiation process of the TH1
or TH2 phenotypes; they induce CD4-positive T cells to differen-
tiate into either T1- or T2-like cells while they inhibit the
differentiation of the antithetical phenotype [58]. For example,
IL-4 is essential for in vitro priming for IL-4 producing cells while
it blocks the priming of precursor TH cells to develop into INF-y
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producers, that is, TH1-like cells [59]. IL-12 enhances but is not
essential for the priming of INF-y producing cells [59]. Although
most work on TH1ITH2 phenotypic distinctions has been done in
murine infectious disease models and initial studies of human
CD4-positive T cell clones failed to show the same degree of
divergence of cytokine production as observed with murine
clones, more recent experiments with antigen-specific T cell
clones have shown a greater degree of TH1/Tfl2 polarization in
human lymphokine-producing phenotypes than observed initially
[60].
Recent data suggest that cytokines, like INF-y and IL-4,
elaborated by CD8-positive cells may also regulate the CD4-
positive cells [60, 61]. Furthermore, renal parenchymal cells
subjected to ischemia produce an array of cytokines including the
TH1-like cytokine INF-y and the TH2-like cytokines IL-6 and
IL-b [62, 63]. Graft antigenic epitopes in conjunction with locally
produced cytokines elaborated by graft invading cells and renal
parenchymal cells as well as recipient prohormone and hormone
levels [64] may participate in the regulation of the T phenotypic
differentiation of graft invading CD4-positive cells.
Several hypothesis have been proposed to explain the immuno-
logical basis of chronic rejection. Chronic rejection could be the
final result of recurrent episodes of acute rejections, that is, TH1
orchestrated cytotoxic T cell and macrophage-mediated tissue
damage [65]. Recurrent episodes of acute rejection, each treated
with immunosuppressive drugs, could persist as a smoldering,
chronic process that leads to protracted tissue damage and
scarring. Consistent with this hypothesis are clinical studies that
have shown that freedom from acute rejection episodes is associ-
ated with an excellent long-term graft outcome [66, 67], although
some transplants develop chronic rejection without previous acute
rejection episodes [42]. Since routine biopsies often show focal
areas of cellular infiltration and inflammation [11, 33, 68], many of
which are CD4-positive, it is conceivable that they represent a
population of TH1-like cells, directing localized acute rejection
which initially remains limited because of the subsequent local
activation of TH2-like cells that release cytokines like IL-4 and
IL-b. These cytokines inhibit the generation and activation of T
cells that direct pro-inflammatory responses, as discussed, and
inhibit the release of IL-i, IL-6 and TNF-cr by cells of the
monocyte lineage, and thus limit the rejection reaction. Repeated
episodes of such subclinical rejection episodes could lead to low
grade, chronic and progressive tissue damage [65].
An alternative but not mutually exclusive hypothesis to explain
chronic rejection is that the immune-regulatory mechanisms that
come into action to prevent acute rejection play a role in chronic
rejection. As inhibition of T1-like responses by immunosuppres-
sive drugs or biological manipulations like blood transfusions may
lead to an ascendency of TH2-like cells, which inhibit THI-like
responses but support B cell responses and antibody formation,
chronic rejection may be a predominantly antibody-mediated
form of graft damage [69].
The vascular lesions of chronic rejection may thus result from
chronic or repeated episodes of TH1-directed acute rejection or
TH2-orchestrated antibody-mediated damage against donor trans-
plantation antigens of the graft vessel wall, especially the endo-
thelium [70]. In vitro and in vivo studies have shown that endo-
thelial cells may serve as target cells for allogeneic cellular and
humoral effector mechanisms [71—74]. A recent histopathological
study of transplants with clinical evidence of acute rejection has
shown that early vascular rejection is strongly correlated with late
graft loss; the five year graft survival rate in this group was 34%
versus 70 to 75% in patients who have never experienced an acute
rejection episode or who had only interstitial rejection in the
biopsy taken during the acute rejection episode.' Of interest is a
similar study in cardiac transplant patients that showed that grafts
with early vascular rejection lesions are more likely to develop
graft atherosclerosis than grafts that undergo early interstitial
rejection episodes [75]. Although acute rejection-associated vas-
culitis may result from both cellular [73] and humoral immune
mechanisms, clinical-pathological studies have shown correlations
between anti-class I-like antibodies and both acute or chronic
vascular rejection in immunosuppressed patients [70, 76, 77],
although it is difficult to establish a cause and effect relationship.
Serial histopathological studies have suggested, however, that the
vascular lesions of chronic rejection arise from delayed-type
hypersensitivity reactions against the graft vessel wall [15].
An experimental study of rat renal transplants with chronic
rejection and transplant glomerulopathy in animals tolerant to
donor class I MHC antigens have shown that such recipients
mount an 1gM antibody response against endothelial cell-specific
alloantigens. Based on immunostaining of tissue specimens, it was
postulated that antibodies against glomerular endothelial cell
specific antigens are involved in the development of the glomer-
ular lesions [78]. We recently found circulating IgG antibodies
against a novel set of donor and third party GBM and TBM
antigens in the post-transplant sera from non-immunosuppressed
rats with chronic renal allograft rejection, but the pathogenetic
significance of the antibodies remains to be established [79]. Thus
the nature and specificity of the immune response involved in
transplant glomerulopathy remains to be established.
Cyclosporine A inhibits the calcium-dependent T cell receptor
signaling pathway that results in the transcription a variety of
cytokine genes, including the genes for IL-2, IL-3, IL-4, granulo-
cyte-macrophage colony stimulating factor, TNF-a, and IFN-y,
many of which are involved in the regulation of the immune
response that leads to acute rejection. However, cyclosporine A
does not inhibit the transcription, translation and secretion of
TGF-13 [80], a cytokine with immunosuppressive properties that
enhances the formation and deposition of extracellular matrix
material [81, 82]. Thus, although antigenic stimulation of T cells in
the presence of cyclosporine A does not lead to cell proliferation
and clonal expansion of antigen-reactive T cells, it does not inhibit
the secretion of the fibrogenic cytokine TGF-/3.
Antigen independent factors that influence tissue remodeling
post-transplantation
There is growing evidence that non-immune or antigen inde-
pendent factors play a role in the late outcome of kidney
transplantation. As discussed, registry data indicate that grafts
from very young, elderly, black or female donors survive less well
than grafts from donors aged 15 to 55, non-black donors or male
donors, with a difference in three-year graft survival between 5
and 20% [49]. It has furthermore been shown that the long-term
1 Van Saase JLCM, Van der Woude FJ, Thorogood J, Hollander
AAMJ, Van Es LA, Weening JJ, Van Bockel JH, Bruijn JA. The relation
between acute vascular and interstitial renal allograft rejection and
subsequent chronic rejection. Submitted.
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graft survival is decreased in overweight recipients [51J. Increased
graft loss from very young donors could represent technical
problems with relatively small renal arteries that do not increase
in caliber with increasing renal size or a disadvantaged effect of a
rapid increase in growth in these initially small kidneys placed in
an adult recipient [83], while the decreased long-term survival of
kidneys from elderly donors could reflect a normal aging-related
reduction in renal mass [84]. Furthermore, difficulties in dosing of
immunosuppressive medication in obese patients could explain
the decreased long-term graft survival in these patients. However,
the poorer long-term survival in these situations could, at least in
part, be explained by a mismatch between recipient metabolic
demands and graft size, maturity or nephron number. The data
are consistent with the hypothesis that a mismatch between
recipient metabolic demand and graft renal mass is associated
with an increased late graft loss [49]. One recently presented,
prospective study showed that the five-year survival rate was more
than 20% lower in recipients with a low graft mass over recipient
body mass ratio compared with combinations with a high graft
mass over body weight ratio [851.
Loss of renal mass leads to an increase in size and function of
the remaining nephrons and includes an increase in glomerular
capillary blood flow and pressure [861, increased glomerular
permeability characteristics [87], glomerular hypertrophy [88],
changes in renal metabolism [89, 90] and lipoprotein disorders
secondary to uremia and proteinuria [91]. Generally, these
changes have been viewed as homeostatic adaptations in response
to an increased work load of surviving nephrons with the resultant
maintenance of more normal metabolic parameters. With the
demonstration that loss of renal mass may lead to the develop-
ment of significant proteinuria and progressive glomerulosclerosis
and impaired renal function [92—95], several of the adaptive
changes have been singled out as potentially deleterious in the
long run, predisposing adapted nephrons to further injury. It is
now clear, however, that several mechanisms may act interactively
or independently to explain the demise in renal function under
different experimental conditions.
Two clinical studies have found a correlation between the
presence of systemic hypertension and an accelerated rate of
deterioration of graft function in chronic rejection [96, 97], but no
data are available that demonstrate improved outcome with strict
blood pressure control [98]. Dietary protein restriction, an inter-
vention that lowers the glomerular capillary pressure but not the
systemic blood pressure under experimental conditions [94],
improves the abnormal permselectivity characteristics of trans-
plants with chronic rejection [99], and two small clinical studies
suggested some benefit of such diets on the rate of progression of
renal failure in chronic rejection [100, 101].
We recently demonstrated in rats that the glomerular capillary
pressure increases following unilateral nephrectomy in some
strains but not in others [102]. Measurements of glomerular
capillary pressures in transplanted kidneys furthermore showed
that the capillary pressure in transplanted kidneys resembles that
of the donor strain as observed after renal ablation [102, 103].
Lowering of the glomerular capillary pressure with anti-hyperten-
sive drugs improves graft survival rate, decreases the amount of
proteinuria and is associated with preservation of the glomerular
structure, while little or no effect was found on the extra-glomer-
ular lesions [104]. Since glomerular hypertension per se cannot
explain the lesions of chronic rejection [102], we hypothesize that
the combination of immune reactivity against allogeneic determi-
nants of glomerular mesangial cells and their extracellular matrix
proteins [79], in conjunction with other processes that lead to
tissue remodeling, such as glomerular hypertension [94], leads to
transplant glomerulopathy.
Experimental and clinical studies have shown an association
between glomerular hypertrophy and the development of glomer-
ulosclerosis [88], which has led to the hypothesis that growth
represents another adverse adaptation of the remaining nephrons.
Several mechanisms have been proposed to explain the deterio-
ration in renal function in these conditions [reviewed in 105].
Although recent morphometric studies have described enlarged
glomeruli in human transplants with chronic rejection [18], an-
other study failed to show a correlation between glomerular
hypertrophy and loss of graft function [971.
Pretranspiant hyperlipidemia is a risk factor for late allograft
loss [45]. Low-density lipoprotein is directly toxic to endothelial
cells and elevated cholesterol concentrations and hyperlipidemia
foster vascular injury, atherosclerosis and glomerulosclerosis [91].
Experimental studies of cardiac transplants have shown that
hypercholesterolemia acts synergistically with allogeneic immune
reactions in the development of graft atherosclerosis [106], but
two clinical studies of renal transplant patients have failed to
establish a correlation between post-transplant hyperlipidemia
and late graft loss [97, 107]. One recent study found that renal
transplant patients with chronic vascular rejection had higher
VLDL, LDL, total cholesterol and triglyceride levels, more triglyc-
eride-rich VLDL and LDL fractions, and a more atherogenic
distribution of the lipoproteins compared with controls [108].
Although impaired renal function and proteinuria may cause lipid
abnormalities, the presence of similar abnormalities in cardiac
transplant patients with graft atherosclerosis [1091 supports the
hypothesis that the hyperlipoproteinemia contributes to the de-
velopment of graft atherosclerosis. This possibility is further
justified by the presence of apolipoproteins Al, A2 and Bi in the
graft vessel wall of human renal allografts with chronic rejection
[110].
Prolonged graft ischemia and delayed graft function are asso-
ciated with decreased short- and long-term graft survival [47, 48],
but the mechanism underlying these observations remains un-
known. Whether specific structural lesions underlie the late
decline in function that occurs in grafts exposed to long episodes
of graft ischemia is uncertain. Although chronic rejection and
ischemia may both result in interstitial fibrosis and increases in
glomerular matrix, GBM abnormalities or vascular lesions as
observed in chronic rejection are not found in ischemia [1111.
Furthermore, the greater impact of ischemia on an allograft
compared with a syngeneic graft argues for an interaction between
ischemia and immune responsiveness. Ischemia results in in-
creased tissue levels of pro-inflammatory mediators, including
cytokines [112, 113] and products of arachidonic acid metabolism
[114], which up-regulate CD1 1/CD 1 8 expression on leukocytes,
increase ICAM-1 and MHC expression on endothelial cells, and
increase CD11/CD18 avidity for ICAM-1 [115, 116]. As a result,
there is increased adherence of leukocytes to endothelial cells,
activation of leukocytes, and increased production of additional
inflammatory mediators. The up-regulation of incompatible trans-
plantation antigens, cell adhesion molecules and cytokines may
increase the immunogenicity and susceptibility of transplanted
organs to allogeneic immune reactions, and may explain excessive
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graft loss from acute rejections of kidneys exposed to long
ischemic periods. It is difficult, however, to explain the association
of ischemia with chronic rejection. Although anti-ICAM-1 mono-
clonal antibodies protect the kidney against ischemic renal failure
[117], it is not known whether they protect against ischemia-
related chronic rejection. It is of interest that the degree of
vascular and glomerular lesions in experimental renal allografts
with chronic rejection correlates with the duration of the periop-
erative ischemia, while there is no correlation with the degree and
extent of cellular inflammation shortly after transplantation [111].
Growth factors and other mediators of tissue remodeling
Antigen-dependent and antigen-independent mechanisms may
control tissue remodeling through the local production of growth
factors that influence cell migration and proliferation as well as
extracellular matrix metabolism. Growth factors are like cyto-
kines, peptide molecules produced by a variety of cells in response
to a range of stimuli, that bind to their receptors on the cell
surface followed by activation of intracellular signal transduction
pathways and nuclear transcription factors. The same peptide can
have both stimulatory and inhibitory activities in a single cell in
vitro, depending on the differentiation state of the cell and the
presence of other growth factors [1181. Therefore, the combina-
tion of growth factors and cytokines, rather than the presence of
one particular growth factor, is the most important determinant
for a given biological response of the cells exposed to them.
Immunological mechanisms like acute rejection reactions [119],
as well as antigen-independent mechanisms like ischemia [62, 63],
glomerular hypertension [120], and lipid deposits [1211 stimulate
the release of various cytokines and growth factors from lymphoid
cells [56, 57], macrophages [122], natural killer cells [123], vascu-
lar wall cells [121] and renal parenchymal cells [63, 124]. The
cytokines and growth factors, in turn, may regulate the prolifera-
tion and metabolic activities of the graft infiltrating cells as well as
the graft cells themselves [121, 123].
Atherosclerotic vessel wall remodeling in response to vascular
injury is an example of a predominantly growth factor-driven
lesion [121, 125]. It was originally proposed that loss of endothe-
hal cell lining results in the formation of platelet thrombi that
adhere to the subendothelium, followed by the release of growth
regulating factors, like platelet-derived growth factor (PDGF).
Proteases and elastases released from the vessel wall or vessel
wall-invading inflammatory cells may cause degradation of extra-
cellular matrix and release of growth factors that have been stored
in an inactive form bound to the extracellular matrix [126, 127].
However, it is now recognized that atherosclerosis may also
develop without loss of endothelial cell lining or obvious endo-
thehial cell damage [128, 129]. Endothelial and smooth muscle
cells may become "activated" during vessel wall injury and
produce a myriad of multifunctional cytokines and growth factors,
while graft wall invading T and B lymphocytes, macrophages, and
NK cells may be additional sources of growth factors and cyto-
kines when appropriately stimulated [58, 122, 123]. As mesangial
cells have many features in common with vascular smooth muscle
cells, it has been proposed that the processes that cause athero-
sclerosis in vessels cause mesangial sclerosis in the glomeruhi
[130].
Transplants with acute or chronic rejection have increased
levels of PDGF receptor and ligand mRNA and proteins in the
vessel wall and the mesangium [131, 1321. PDGF is one of the best
characterized mitogens for smooth muscle and mesangial cells in
vitro and enhances collagen and elastin synthesis. It is produced
and released by a variety of cells including platelets, monocytes
and macrophages, endothelial cells, vascular smooth muscle cells
and mesangial cells [reviewed in 133]. The importance of the
PDGF system in the glomerular response to injury has been
illustrated in experimental glomerulonephritis [1341.
Transforming growth factor-f3 (TGF-/3), a polypeptide growth
factor produced by a large number of different cell types, includ-
ing monocytes, macrophages, neutrophils, T lymphocytes, B lym-
phocytes and glomerular cells [80, 135, 136], has potent immuno-
suppressive properties [136—138], induces epithehial cells to
synthesize fibronectin and stimulates cultured mesangial and
glomerular epithelial cells to produce decorin and biglycan [82].
Enhanced extracellular matrix formation in conjunction with
decreased matrix degradation, results in increased net deposition
of extra cellular matrix material and fibrosis [135]. Sustained renal
expression of TGF-p has indeed been shown to be associated with
progressive fibrosis [82]. Northern blots have shown up-regulation
of TGF-f3 mRNA in allogeneic rat kidney grafts with or without
clinical or histological evidence of rejection [131], and quantita-
tive measurements of TGF-J3 transcripts in human renal trans-
plant biopsies have demonstrated a correlation between TGF-f3
mRNA levels and interstitial fibrosis [139]. The interstitial accu-
mulation of cellular derived fibronectin and tenascin, glycopro-
teins involved in architectural tissue remodeling, in acute and
chronic rejection has been attributed to the local TGF-f3 produc-
tion [140].
IL-6 is a mitogen for smooth muscle and mesangial cells [141],
although it inhibited mesangial cell growth in one study [142].
Human renal allografts have increased levels of IL-6 transcripts in
glomerular, tubular, vascular and graft infiltrating cells during
acute rejection [143] and immunohistochemistry of rat renal
allografts with chronic rejection have shown IL-6 protein in the
mesangium and the mononuclear cells that invade the glomeruli
[144].
Of interest are recent studies of experimental cardiac trans-
plants that have shown that soluble tumor necrosis factor recep-
tors or a monoclonal antibody against interferon-y inhibit vascular
intimal proliferation [145, 146]. The list of other growth factors
and cytokines potentially involved is long and include IL-i,
fibroblast growth factors, angiotensin II, and many others as
reviewed elsewhere [133]. However, the direct evidence linking
chronic rejection to specific cytokines is limited, and the roles of
the various mediators and combinations of cytokines and growth
factors can only be assessed critically when strategies become
available that allow long-term suppression of their production or
blocking of their signal transduction pathways.
In addition to vessel wall proliferation in response to locally-
produced growth factors, vascular smooth muscle cells may also
proliferate as a result of loss of natural proliferation inhibitors
such as the extracellular heparan sulfate proteoglycan matrix. Of
interest are studies that have shown that exogenous administra-
tion of low molecular weight heparins have a beneficial effect on
the vascular lesions of chronic rejection in experimental cardiac
transplants [147, 148].
Summary and conclusions
Chronic rejection results from recurrent episodes of subclinical
or clinically evident acute rejection, with or without involvement
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Tissue reactions
in response to injury
Immune-mediated
tissue damage
Adaptations in response
to loss of renal mass
Fig. 1. Proposed mechanisms that lead to chronic renal allograft loss.
of chronic rejection-specific allogeneic immune mechanisms. The
tissue damage occurs over a prolonged period of time, which
allows the emergence of antigen-independent tissue repair mech-
anisms and intrarenal adaptations in response to progressive loss
of renal mass (Fig. 1). The combination of these mechanisms
leads, very likely, to the tissue remodeling of chronic rejection.
The heterogeneous expression of chronic rejection may result
from different types and specificities of allogeneic immune reac-
tions as well as different contributions of antigen-independent
factors that modulate the antigen-dependent tissue responses to
injury. The extent to which these mechanisms participate in the
overall picture is presently unknown as immunological parameters
are not measured routinely in the follow-up of patients with
chronic graft dysfunction. Furthermore, some grafts may undergo
tissue remodeling as a consequence of predominantly antigen-
independent mechanisms. Therefore, the term chronic allograft
dysfunction may clinically be preferable over chronic rejection to
describe the gradual decline in graft function months or years
after transplantation in the absence of a well-defined mechanism
or an accepted treatment.
Acknowledgments
LEENDERT C. PAUL
Toronto, Ontario, Canada
Work in the author's laboratoly was supported by grants from the
Kidney Foundation of Canada, the Heart and Stroke Foundation of
Canada, and the Medical Research Council of Canada. The author is the
incumbent of the Keenan Research Chair in Medicine at the University of
Toronto and St. Michael's Hospital.
Reprint requests to Dr. L. C. Paul, Division of Nephrology, University of
Toronto at St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B
1W8, Canada.
References
1. SCHWEITZER EJ, MATA5 AJ, GILLINGHAM KJ, PAYNE WD, GORES
PF, DUNN DL, SUTHERLAND DER, NAJARIAN iS: Causes of renal
allograft loss. Ann Suig 214:679—688, 1991
2. CooK DJ: Long term survival of kidney allografts, in Clinical
Transplants 1987, edited by TERASAKI Pt, Los Angeles, UCLA Tissue
Typing Laboratory, 1987, pp 277—285
3. ALMOND PS, MATAS A, GILLINGHAM KJ, DUNN DL, PAYNE WD,
GORES P, GRUESSNER R, NAJARIAN JS: Risk factors for chronic
rejection in renal allograft recipients. Transplantation 55:752—757,
1993
4. YILMAZ S, HAYRY P: The impact of acute episodes of rejection on
the generation of chronic rejection in rat renal allografts. Transplan-
tation 56:1153—1156, 1993
5. CHEIGH JS, STENZEL KH, SUSIN M, RUBIN AL, RIGGIO RR, WHIT-
SELL JC: Kidney transplant nephrotic syndrome. Am J Med 57:730—
740, 1974
6. PAUL LC, HAYRI P, FOEGH M, DENNIS Mi, MIHATSCH M, LARSSON
E, FELLSTROM B: Diagnostic criteria for chronic rejection/acceler-
ated graft atherosclerosis in heart and kidney transplants: Proposal
from the Fourth Alexis Carrel Conference on Chronic Rejection and
Accelerated Arteriosclerosis in Transplanted Organs. Transplant
Proc 25:2020—2021, 1993
7. KIRKMAN RL, STROM TB, WEIR MR, TILNEY NL: Late mortality and
morbidity in recipients of long-term allografts. Transplantation 34:
347—351, 1982
8. PAUL LC, FELLSTROM B: Chronic vascular rejection of the heart and
the kidney—Have rational treatment options emerged? Transplan-
tation 53:1169—1179, 1992
9. RAo Ky, KASISKE BL, BLOOM PM: Acute graft rejection in the late
survivors of renal transplantation. Clinical and histological observa-
tions in the second decade. Transplantation 47:290—292, 1989
10. FOSTER MC, DENNIS MJS: Chronic renal graft rejection, in Organ
Transplantation: Long Term Results, edited by PAUL LC, SOLEZ K,
New York, Marcel Dekker Inc, 1992, pp 153—172
11. MASON DW, MORRIS PJ: Effector mechanisms in allograft rejection.
Ann Rev Immunol 4:119—145, 1986
12. NADASDY T, KRENACS T, KALMAR KN, CSAJBOK E, BOUDA K,
ORMOS J: Importance of plasma cells in the infiltrate of renal
allografts. An immunohistochemical study. PatholRes Pract 187:178—
183, 1991
13. STEIN-OAKLEY AN, JABLONSKI P, TZANIDIS A, BAXTER K, HOWDEN
BO, MARSHALL VC, THOMSON NM: Development of chronic injury
and nature of interstitial infiltrate in a model of chronic renal
allograft rejection. Transplantation 56:1299—1305, 1993
14. PAUL LC, GROTFIMAN GT, BENEDIKTSSON H, DAVIDOFF A, ROZING
J: Macrophage subpopulations in normal and transplanted heart and
kidney tissues in the rat. Transplantation 53:157—162, 1992
15. GOULDESBROUGH DR, AXELSEN RA: Arterial endothelialitis in
chronic renal allograft rejection: A histopathological and immuno-
cytochemical study. Nephrol Dial Transplant 9:35—40, 1994
16. MONGA G, MAzzucco G, MESSINA M, MOTITA M, QUARANTA S,
NOVARA R: Intertubular capillary changes in kidney allografts: a
morphologic investigation on 61 renal specimens. Mod Pathol 5:125—
130, 1992
17. MERRILL JP: Glomerulonephritis in renal transplants. Transplant
Proc 1:994—1004, 1969
18. BARRIENTOS A, PORTOLES J, HERRERO JA, TORRALBO A, PRATS D,
GUT!ERREZ-MILLET V, BLANCO J: Glomerular hyperfiltration as a
nonimmunologic mechanism of progression of chronic renal rejec-
tion. Transplantation 57:753—756, 1994
19. ETrENGER RB, HEUSER ET, MALEKZADEH MH, PENNISI AJ, UIT-
TENBOGAART CM, FINE RN: Focal glomerulosclerosis in renal al-
lografts. Association with the nephrotic syndrome and chronic
rejection. Am J Dis Child 131:1347—1352, 1977
20. CHEIGH JS, MOURADIAN J, SOLIMAN M, TAPAI L, RIGGI0 RR,
STENZEL KH, RUBIN AL: Focal segmental glomerulosclerosis in
renal transplants. Am J Kidney Dis 2:449—455, 1983
21. HAMBURGER J, CROSNIER J, DORMONT JA: Observations in patients
with a well tolerated homotransplanted kidney. Ann NY Acad Sci
120:558—577, 1964
22. ROSSMANN P, JIRKA J, MALEK P, HEJNAL J: Glomerulopathies in
human renal allografts. Beitr Pathol Bd 155:18—35, 1975
23. OI.SEN S, BOHMAN S-O, PETERSEN VP: Ultrastructure of the glomer-
ular basement membrane in long term renal allografts with trans-
plant glomerular disease. Lab Invest 30:176—189, 1974
24. PETERSEN VP, OLSEN TS, KISSMEYER-NIELSEN F, BOI-IMAN SD,
HANSEN HE, HANSEN ES, SKov PE, SOLLING K: Late failure of
human renal transplants. An analysis of transplant disease and graft
failure among 125 recipients surviving for one to eight years.
Medicine 54:45—71, 1975
25. BUSCH GJ, GALVANEK EG, REYNOLDS ES: Human renal allografts.
Analysis of lesions in long-term survivors. Human Pathol 12:253—298,
1971
26. ZOLLINGER HU, MOPPERT J, THIEL G, ROHR HP: Morphology and
Scarring
Paul: Chronic renal transplant loss 1497
pathogenesis of glomerulopathy in cadaver kidney allografts treated
with antilymphocyte globulin. Curr Top Pathol 57:1—48, 1973
27. CAMERON JS, TURNER DR: Recurrent glomerulonephritis in a!-
lografted kidneys. Clin Nephrol 7:47—54, 1977
28. HABIB R, ANTIGUA C, HINGLAIS N, GAGNADOUX MF, BROYER M:
Glomerular lesions in the transplanted kidney in children. Am J
Kidney Dis 10:198—207, 1987
29. OI.SEN TS: Pathology of allograft rejection, in Kidney Transplant
Rejection, (2nd cd) edited by BURDICK JF, RACUSEN LC, SOLEz K,
New York, Marcel Dekker mc, 1992, pp 333—357
30. HABIB R, ZUROWSKA A, HINGLAIS N, GUBLER MC, ANTIGNAC C,
NIAUDET P, BROYER M, GAGNADOUX MF: A specific glomerular
lesion of the graft: Allograft glomerulopathy. Kidney lot 44 (Suppi
42):S104—S111, 1993
31. HABIB R, BROYER M: Clinical significance of allograft glomerulopa-
thy. Kidney mt 44 (Suppl 43):S95—S98, 1993
32. ISONIEMI HM, KROGERUS L, VON WIL[.EBRAND E, TASKINEN E,
AHONEN J, HAYRY P: Histopathological findings in well-functioning,
long-term renal allografts. Kidney mt 41:155—160, 1992
33. Rusu DN, HENRY SF, JEFFERY JR, SCHROEDER TJ, COUGH J:
Histological findings in early routine biopsies of stable renal allograft
recipients. Transplantation 57:208—211, 1994
34. NAIMARK DMJ, COLE E: Determinants of long-term renal allograft
survival. Transplant Rev 8:93—1 13, 1994
35. TERASAKI P1, CECKA JM, GJERTSON DW, CHO Y, TAKEMOTO S,
COHN M: A ten year prediction for kidney transplant survival, in
Clinical Transplants, 1992, edited by TERASAKI PT, CECKA JM, Los
Angeles, UCLA Tissue Typing Laboratory, 1993, pp 501—512
36. THoR0000D J, VAN HOUWELINGEN HC, VAN RooD JJ, ZANTVOORT
FA, SCHREUDER GMT, PERSIJN GG: Long-term results of kidney
transplantation in Eurotranspiant, in Organ Transplantation: Long
Term Results, edited by PAUL LC, SOLEZ K, New York, Marcel
Dekker mc, 1992, pp 33—56
37. OPELz G, FOR THE COLLABORATIVE TRANSPLANT STUDY: Collabora-
tive transplant study—lU-year report. Transplant Proc 24:2342—2355,
1992
38. CECKA JM, TERASAKI PJ: The UNOS Scientific renal transplant
registry, in Clinical Transplants, 1992, edited by TERASAKI PT, CEcKA
JM, Los Angeles, UCLA Tissue Typing Laboratory, 1993, pp 1—16
39. CECKA JM: Outcome statistics of renal transplants with an emphasis
on long-term survival. Clin Transplant 8:324—327, 1994
40. CECKA JM, TERASAKI P1: Early rejection episodes, in Clinical Trans-
plants 1989, edited by TERASAKI PT, Los Angeles, UCLA Tissue
Typing Laboratory, 1989, pp 425—434
41. MATAS AJ, GILLINGHAM KJ, PAYNE WD, NAJARIAN JS: The impact
of an acute rejection episode on long-term renal allograft survival
(t112). Transplantation 57:857—859, 1994
42. IsONIEMI H, NURMINEN M, TIKKANEN MJ, VON WILLEBRAND E,
KROGERUS L, AHONEN J, EKIUND B, HOCKERSTEDT K, SALMELA K,
HAYRY P: Risk factors predicting chronic rejection of renal al-
lografts. Transplantation 57:68—72, 1994
43. BURKE JF, PIRSCH JD, RAMOS EL, SALOMON DR, STABLEIN DM,
VAN BUREN DH, WEST JC: Long-term efficacy and safety of cyclo-
sporine in renal-transplant patients. N Englf Med 331:358—363, 1994
44. Bii-r AE, KEITEL E, GARCIA CD, BRUNO RM, SILVIERA AE,
MESSIAS A, GARCIA VD: Patient non-compliance as a cause of late
kidney graft failure. Transplant Proc 24:2720—2721, 1992
45. DIMIINY E, WAHLBERC J, LITHLI,L. H, FEILSTROM B: Hyperlipidae-
mia in renal transplantation. Risk factor for long-term graft outcome,
in Metabolic Factors and Outcome of Organ Transplantation, edited by
DIMENY E, Academic thesis, Uppsala University, Sweden, 1994
46. CHO YW, TERASAKI PT, GRAVER B: Fifteen year kidney graft
survival, in Clinical Transplants 1989, edited by TERASAKI PT, Los
Angeles, UCLA Tissue Typing Laboratory, pp 325—334
47. SANFILIPPO F, VAUGHN WK, SPEES EK, LUCAS BA: The detrimental
effects of delayed graft function in cadaver donor renal transplanta-
tion. Transplantation 38:643—648, 1984
48. HALLORAN PF, APRILE MA, FAREWELL V, LUDwIN D, SMITH ER,
TASI SY, BEAR RA, COLE EH, FENTON SS, CATFRAN DC: Early
function as the principal correlate of graft survival. Transplantation
46:223—228, 1988
49. BRENNER BM, COHEN RA, MIIFORD EL: In renal transplantation,
one size may not fit all. JASN 3:162—169, 1992
50. YUGE J, CECKA JM: Sex and age effects in renal transplantation, in
Clinical Transplants 1991, edited by TERASAKI PT, Los Angeles,
UCLA Tissue Typing Laboratory, pp 257—267
51. TERASAKI PT, KOYAMA H, CECKA JM, GJERTSON DW: The hyperfil-
tration hypothesis in human renal transplantation. Transplantation
57:1450—1454, 1994
52. GRATI-FAN MT, MORENO-CABRAL CE, STARNES VA, OYER PE,
STINSON EB, SHUMWAY NE: Cytomegalovirus infection is associated
with cardiac allograft rejection and atherosclerosis. JAMA 261:3561—
3566, 1989
53. RICHARDSON WP, C0LVIN RB, CHEESEMAN SK, TOLKOFF-RUBIN NE,
HERRIN JT, COSIMI AB, COLLINS AB, HIRSCH MS, MCCLUSKEY RT,
RUSSELL PS, RUBIN RH: Glomerulopathy associated with cytomeg-
alovirus viremia in renal allografts. N Engl J Med 305:57—63, 1981
54. TUAZON TV, SCHNEEBERGER EE, BAHN AK, MCCLUSKEY RT,
C0SIMI AB, SCHOOLEY RT, RUBIN RH, COLVIN RB: Mononuclear
cells in acute allograft glomerulopathy. Am / Pathol 129:119—132,
1987
55. HERRERA GA, ALEXANDER RW, COOLEY CF, LUKE RG, KELLY DR,
CURTIS JJ, GOCKERMAN JP: Cytomegalovirus glomerulopathy: A
controversial lesion. Kidney mt 29:725—733, 1986
56. MOSMANN TR, CHERWINSKI H, BOND MW, GIEDLLIN MA, COFFMAN
RL: Two types of murine helper T cell clone. I. Definition according
to profiles of lymphokine activities and secreted proteins. J Immunol
136:2348—2357, 1986
57. STREET NE, MOSMANN TR: Functional diversity of T lymphocytes
due to secretion of different eytokine patterns. FASEB /5:171—177,
1991
58. PAUL WE, SEDER RA: Lymphocyte responses and cytokines. Cell
76:241—251, 1994
59. SEDER RA, PAUL WE, DAVIS MM, FAZEKAS DE ST GROTI-I B: The
presence of interleukin-4 during in vitro priming determines the
lymphokine-producing potential of CD4 from T cell receptor
transgenic mice. JExp Med 176:1091—1098, 1992
60. ROMAGNANI 5: Human TH1 and TH2 subsets: Doubt no more.
Immunol Today 12:256—257, 1991
61. KEMENY DM, NOBLE A, HOLMES BJ, DIAZ-SANCHEZ D: Immune
regulation: A new role for the CD8 cell. Immunol Today 15:107—
110, 1994
62. BROSKI AP, HALLORAN PF: Tissue distribution of IL-lO mRNA in
nomal mice: Expression is T and B cell independent and increased by
irradiation. Transplantation (in press)
63. ONG ACM, FINE LG: Tubular-derived growth factors and cytokines
in the pathogenesis of tubulointerstitial fibrosis: implications for
human renal disease progression. Am J Kidney Dis 23:205—209, 1994
64. RooK GAW, HERNANDEZ-PANDO R, LIGHTMAN SL: Hormones,
peripherally activated prohormones and regulation of the ThlITh2
balance. Immunol Today 15:301—303, 1994
65. LOWRY RP, TAKEUCHI T, CREMISI H, KONIECZNY B, SOMEREN A:
Chronic rejection of organ allografts may arise from injuries sus-
tained in recurring foci of acute rejection that resolve spontaneously.
Transplant Proc 25:2103—2105, 1993
66. LAND W, SCHNEEBERGER H, SCHLEIBNER 5, ILLNER WD, ABEN-
DROTH D, HILLEBRAND G, GOKEL JM, ALBERT E: Long-term results
in cadaveric renal transplantation under cyclosporine therapy. Trans-
plant Proc 23:1244—1246, 1991
67. TF..SI Ri, HENRY ML, ELKHAMMAS EA, FERGUSON RM: Predictors of
long-term primary cadaveric renal transplant survival. Clin Trans-
plant 7:345—352, 1993
68. SOLEZ K, AXELSEN RA, BENEDIKTSSON H, BURDICK JF, COHEN AH,
COLVIN RB, CROKER BP, DROZ D, DUNNILL MS, HALLORAN PF,
HAYRY P, JENNErrE JC, KEOWN PA, MARCUSSEN N, MIHATSCH Mi,
M0R0zAMI K, MYERS BD, NAST CC, OLSEN 5, RACUSEN LC, RAMOS
EL, ROSEN S, SACHS DH, SALOMON DR, SANFILIPPO F, VERANI R,
VON WILLEBRAND E, YAMAGUCHI Y: International standardization
of criteria for the histologic diagnosis of renal allograft rejection: The
Banif working classification of kidney transplant pathology. Kidney
mt 44:411—422, 1993
69. HUTCHINSON IV: Tmmunological mechanisms of long-term graft
acceptance, in Organ Transplantation. Long-Term Results, edited by
PAUL LC, SoLEz K, New York, Marcel Dekker mc, 1992, pp 1—31
70. PAul. LC, BALDWIN WM, VAN ES LA: Vascular endothelial alloan-
tigens in renal transplantation. Transplantation 40:117—123, 1985
1498 Paul: Chronic renal transplant loss
71. COLSON YL, MARKUS BH, ZEEVI A, DUQUESNOY RJ: Interactions
between endothelial cells and alloreactive T cells involved in graft
immunity. Transplant Proc 20:273—275, 1988
72. MILTENBURG AMM, MEIJER-PAAPE ME, DAHA MR, PAUL LC:
Endothelial cell lysis induced by lymphokine activated human pe-
ripheral blood mononuclear cells. EurJlmmunol 17:1383—1386, 1987
73. BENDER JR, PARDI R, ENGLEMAN E: T-cell receptor-negative natural
killer cells display antigen-specific cytotoxicity for microvascular
endothelial cells. Proc NatI Acad Sci USA 87:6949—6953, 1990
74. PAUL LC, BENEDIKTSSON H, DAVIDOFF A, ISSEKUTZ TB: Effect of
LFA-1 and VLA-4 antibody treatment on rat vascularized cardiac
allograft rejection. Transplantation 55:1196—1199, 1993
75. HAMMOND EH, YOWELL RL, PRICE GD, MENLOVE RL, OLSEN SL,
O'CONNELL JB, BRIsTow MR, DOTY DB, MILLAR RC, KARWANDE
SV, JONES KW, GAY WA JR, RENLUND DG: Vascular rejection and
its relationship to allograft coronary artery disease. J Heart Lung
Transplant 11:S111—S119, 1992
76. HALLORAN PF, SCHLAUT J, SOLEZ K, SRINIVASA NS: The significance
of the anti-class I response. II Clinical and pathologic features of
renal transplants with anti-class I-like antibody. Transplantation
53:550—555, 1992
77. JEANNET M, PINN VW, FLAX MH, RUSSELL HS: Humoral antibodies
in renal allotransplantation in man. N Engl J Med 282:111—117, 1970
78. DUIJVESTIJN AM, VAr' BREDA VRIESMAN PJC: Chronic renal al-
lograft rejection. Selective involvement of the glomerular endothe-
hum in humoral immune reactivity and intravascular coagulation.
Transplantation 52:195—202, 1991
79. D HEER E, DAVIDOFF A, VAN DER WAL A, VAN GEEST M, PAUL
LC: Chronic renal allograft rejection in the rat. Transplantation-
induced antibodies against basement membrane antigens. Lab Invest
70:494—502, 1994
80. U B, SEHAJPAL PK, KHANNA A, VLASSARA H, CERAMI A, STENZEL
KH, SUTHANTHIRAN M: Differential regulation of transforming
growth factor /3 and interleukin 2 genes in human T cells: Demon-
stration by usage of novel competitor DNA constructs in the
quantitative polymerase chain reaction. J Exp Med 174:1259—1262,
1991
81. JONES CL, BUCH S, POST M, MCCULLOCH L, Liu E, EDDY AA:
Pathogenesis of interstitial fibrosis in chronic purine aminonucleo-
side nephrosis. Kidney mt 40:1020—1031, 1991
82. YAMAMOTO T, NOBLE NA, MILLER DE, BORDER WA: Sustained
expression of TGF-p1 underlies development of progressive kidney
fibrosis. Kidney mt 45:916—927, 1994
83. WOOLLEY AC, ROSENBERG ME, BURKE BA, NATH KA: De novo
focal glomerulosclerosis after kidney transplantation. Am J Med
84:310—315, 1988
84. RA0 Ky, KASISKE BL, ODLUND MD, NEY AL, ANDERSEN RC:
Influence of cadaver donor age on post-transplant renal function and
graft outcome. Transplantation 49:91—95, 1990
85. ROTH D, BURKE G, NERY J, ESQUENAZI V, MILLER J: Nephron
dosing in renal transplantation: how much kidney is sufficient?
(abstract) 13th Annual Meeting, American Society of Transplant
Physicians, Chicago, 1994, p 50
86. HOSTEJTER TH, OLSON JL, RENNKE HG, VENKATACHALAN MA,
BRENNER BM: Hyperfiltration in remnant nephrons: A potentially
adverse response to renal ablation. Am J Physiol 241:F85—F93, 1981
87. REMUZZI 0, BERTANI T: Is glomerulosclerosis a consequence of
altered glomerular permeability to macromolecules? Kidney mt
38:384—394, 1990
88. YOSHIDA Y, Fooo A, IcHOLAwA I: Glomerular hemodynamic
changes vs. hypertrophy in experimental glomerular sclerosis. Kidney
Jut 35:654—664, 1989
89. NATH KA, HOSTETFER MK, HOSTETFER TH: Pathophysiology of
chronic tubulointestitial disease in rats: Interactions of dietary acid
load, ammonia and complement component C3. J Clin Invest 76:667—
675, 1985
90. ALFREY AC: Role of iron and oxygen radicals in the progression of
chronic renal failure. Am J Kidney Dis 23:183—187, 1994
91. KEANE WF, KASISKE BL, O'DONNELL MP: Lipids and progressive
glomerulosclerosis. Am J Nephrol 8:261—271, 1988
92. SHIMURA T, MORRISON AB: A progressive glomerulosclerosis occur-
ring in partial five-sixth nephrectomized rats. Am J Pathol 79:95—106,
1975
93. ANDERSON S, RENNKE HG, BRENNER BM: Therapeutic advantage of
converting enzyme inhibitors in arresting progressive renal disease
associated with systemic hypertension in the rat. J Clin Invest
77:1993—2000, 1986
94. BRENNER BM, MEYER TW, HOSTETI'ER Th: Dietary protein intake
and the progressive nature of kidney disease: The role of hemody-
namically mediated glomerular injury in the pathogenesis of progres-
sive glomenilar sclerosis in aging, renal ablation, and intrinsic renal
disease. N Engl J Med 307:652—659, 1982
95. Novci AC, GEPHARDT G, Guz B, STEINMULLER D, TUBBS RR:
Long-term follow-up after partial removal of a solitary kidney. N
Englf Med 325:1058—1062, 1991
96. MODENA FM, HOSTETFER TH, SALAHUDEEN AK, NAJARIAN JS,
MATAS AJ, ROSENBERG ME: Progression of kidney disease in chronic
renal transplant rejection. Transplantation 52:239—244, 1991
97. Biz'e PC, PIRSCH JD, BELZER FO: Factors affecting renal allograft
function in long-term recipients. Am J Kidney Dis 19:558—566, 1992
98. CHEIGH JS, HASCHEMEYER RH, WANG JCL, RIGGLO RR, TAPIA L,
STENZEL KR, RUBIN AL: Hypertension in kidney transplant recipi-
ents. Effect on long-term renal allograft survival. Am J Hypertens
2:341—348, 1989
99. SALAHUDEEN AK, HOSTErrER TH, RAATZ SK, ROSENBERG ME:
Effects of dietary protein in patients with chronic renal transplant
rejection. Kidney mt 41:183—190, 1992
100. FEEHALLY J, BENNETt SE, HARRIS KPG, WALL J: Is chronic renal
transplant rejection a non-immunological phenomenon? Lancet
2:486—488, 1986
101. Koorr AMM, 'T HART-EERDMANS M, PAUL LC: Dietary protein
manipulation or cyclosporine therapy in chronic renal allograft
rejection. Clin Transplant 2:152—159, 1988
102, KINGMA I, CHEA R, DAVIDOFF A, BENEDIKTSSON H, PAUL LC:
Glomerular capillary pressures in long-surviving rat renal allografts.
Transplantation 56:53—60, 1993
103. JUNAID A, KREN SM, ROSENBERG ME, NATH K, HOSTETrER TH:
Physiological and structural responses to chronic experimental al-
lograft injury. Am J Physiol 267:F1 102—Fl 107, 1994
104. PAUL LC: Functional and histological characteristics of chronic renal
allograft rejection. Cliii Transplant 8:319—323, 1994
105. HOSTETIER TH: Chronic transplant rejection. Kidney Jut 46:266—279,
1994
106. FELLSTROM B, DIMENY E, LARSSON E, CLAESSON K, TUFVESON G:
Rapidly proliferating arteriopathy in cyclosporin-induced perma-
nently surviving rat cardiac allografts simulating chronic vascular
rejection. Clin Exp Immunol 80:288—292, 1990
107. KNIGHT RJ, KERMAN RH, WELSH M, GOLDEN D, SCHOENBERG L,
VAN BUREN CT, LEWIS RM, KAHAN BD: Chronic rejection in
primary renal allograft recipients under cyclosporine-prednisone
immunosuppressive therapy. Transplantation 51:355—359, 1991
108. DIMENY E, FELLSTOM B, LARSSON E, TUFVESON G, LITHELL H:
Chronicvascular rejection and hyperlipoproteinemia in renal trans-
plant patients. Clin Transplant 7:482—490, 1993
109. EICH D, THOMPSON JA, Ko DJ, HASTILLO A, LOWER R, KATZ 5,
KATZ M, HESS MJ: Hypercholesterolemia in long-term survivors of
heart transplantation: An early marker of accelerated coronary
artery disease. J Heart Lung Transplant 10:45—49, 1991
110. V0LLMER E, BOSSE A, BOGEHOLZ J, ROESSNER A, BLASIUS S,
FAI-IRENKAMI' A, BOCKER W: Apolipoproteins and immunohistolog-
ical differentiation of cells in the arterial wall of kidneys in transplant
arteriopathy. Morphological parallels with atherosclerosis. Pathol
Res Pract 187:957—962, 1991
111. YILMAZ 5, PAAVONEN T, HAYRI P: Chronic rejection of rat renal
allografts. II The impact of prolonged ischemia time on transplant
histology. Transplantation 53:823—827, 1992
112. CourrI LM, REMICK DG, BURTCI-I GD, KUNKELSL, STRIETER RM,
CAMPBELL DA JR: Role of tumor necrosis factor-alpha in the
pathophysiologic alterations after hcpatic ischemia/rcperfusion in-
jury in the rat. J Clin Invest 85:1936—1943, 1990
113. GoEs N, RAMASSAR V, URMSON J, HALLORAN PF: Cytokine and
growth factor changes after ischemic injury to the kidney. Abstr Am
Soc Transplant Phys, 1994, Chicago
114. KLAUSNER JM, PATERSON IS, GOLDMAN G, K0EzIK L, RODZEN C,
LAWRENCE R, VALERI CR, SHERPO D, HECHTMAN HB: Post-ischemic
Paul: Chronic renal transplant loss 1499
renal injury is mediated by neutrophils and leukotrienes. Am J
Physiol 256:F794—F802, 1989
115. SHOSKES DA, PARFREY NA, HALLORAN PF: Increased major histo-
compatibility complex antigen expression in unilateral ischemic acute
tubular necrosis in the mouse. Transplantation 49:201-207, 1990
116. SPRINGER T: Adhesion receptors of the immune system. Nature
346:425—434, 1990
117. KELLY KJ, WILLIAMS WW, C0LvIN BB, BONVENTRE JV: Antibody to
intercellular adhesion molecule 1 protects the kidney against isch-
emic injury. Proc NatlAcad Sci USA 91:812—816, 1994
118. SPORN MB, ROBERTS AB: Peptide growth factors are multifunc-
tional. Nature 332:217—219, 1988
119. DALLMAN MJ: The cytokine network and regulation of the immune
response to organ transplants. Transplant Rev 6:209—222, 1992
120. CoR1s P, RISER BL, ZHAO X, NARINS RG: Glomerular volume
expansion and mesangial cell mechanical strain: mediators of gb-
merular pressure injury. Kidney mt 45 (Suppl 45):S11—S16, 1994
121. Ross R: The pathogenesis of atherosclerosis: A perspective for the
1990s. Nature 362:801—809, 1993
122. JOHNSON RB: Monocytes and macrophages. N Engi J Med 318:747—
752, 1988
123. PERUSSIA B: Lymphokine-activated killer cells, natural killer cells
and cytokines. Curr Opin Immunol 3:49—55, 1991
124. YARD BA, DAHA MR, KOOYMANS-COUTHINO M, BRUIJN JA, PAAPE
ME, SCHRAMA E, VAN Es LA, VAN DER WOUDE FJ: IL-i alpha
stimulated TNF alpha production by cultured human proximal
tubular epithelial cells. Kidney mt 42:383—389, 1992
125. KuNclo GS, NEILSON EG, HAVERTY T: Mechanisms of tubulointer-
stitial fibrosis. Kidney mt 39:550—556, 1991
126. KOBAYASHI J, ZHU L, RABINOVITCH M, RABINOVITCI-I Z: Serum
stimulation of elastase in vascular smooth muscle cells. (abstract)
FASEB J (V7):A795, 1993
127. LINDNER V, LAPPI DA, BAIRD A, MAJACK RA, REIDY MA: Role of
basic fibroblast growth factor in vascular lesion formation. Circ Res
68:106—113, 1991
128. PRESCOTIT MF, MCBRIDE CK, COURT M: Development of intimal
lesions after leukocyte migration into the vascular wall. Am J Pathol
135:835—846, 1989
129. Koo EWY, GOTLIEB Al: Endothelial stimulation of intimal cell
proliferation in a porcine aortic organ culture. Am J Pathol 134:497—
503, 1989
130. DIAMOND JR, KARNOVSKY MJ: Focal and segmental glomeruloscle-
rosis: Analogies to atherosclerosis. Kidney mt 33:917—924, 1988
131. PAUL LC, SArro K, NGO K, DAVIDOFF A: Growth factors and
receptor expression in rat renal allografts. (abstract) JASN 3:847,
1992
132. FELLSTROM B, KLARESKOG L, HELDIN C-H, LARSSON E,
RONNSTRAND L, TERRACIO L, TUFVESON G, WAHLBERG J, RUBIN K:
Platelet-derived growth factor receptors in the kidney-upregulated
expression in inflammation. Kidney mt 36:1099—1102, 1989
133. PAUL LC, SOLEZ K: Chronic rejection in vascularized organ a!-
lografts, in Organ Transplantation: Long-Term Results, edited by
PAUL LC, SOLEZ K, New York, Marcel Dekker mc, 1992, pp 99—134
134. JOHNSON R, IIDA H, YosH1MuR A, FLOEGE J, BOWEN-POPE DF:
Platelet-derived growth factor: A potentially important cytokine in
glomerular disease. Kidney mt 41:590—594, 1992
135. WALTENBERGER J, MIYAZONo K, FUNA K, WANDERS A, FELLSTROM
B, HELDIN C-H: Transforming growth factor-a and organ transplan-
tation. Transplant Proc 25:2038—2040, 1993
136. KEHRL JH, WAKEFIELD LM, ROBERTS AB, JAKOWLEW S, ALVEREZ-
MON M, DERYNCK R, SPORN MB, FAUCI AS: Production of trans-
forming growth factor beta by human T lymphocytes; its potential
role in the regulation of T cell growth. J Exp Med 163:1037—1050,
1986
137. WALLICK SC, FIGARI IS, MORRIS RE, LEVINSON AD, PALLADINO
MA: Immunoregulatory role of transforming growth factor beta
(TGF-beta) in development of killer cells; comparison of active and
latent TGF-beta-1. J Exp Med 172:1777—1784, 1990
138. VERBANAC KM, CARVER FM, HAISCH CE, THOMAS JM: A role for
transforming growth factor-beta in the veto mechanism in transplant
tolerance. Transplantation 57:893—900, 1994
139. XU G, WANG JC, LI B, SERUR D, MOURADIAN KH, STENZEL KH,
SUTHANTHIRAN M: Human renal graft rejection: Molecular charac-
terization including quantification of intragraft gene expression.
(abstract) Am Soc Transplant Phys, Houston, 1993, p 161
140. GOULD VE, MARTINEZ-LACABE V, VIRTANEN I, SAHLIN KM,
SCHWARTZ MM: Differential distribution of tenascin and cellular
fibronectins in acute and chronic renal allograft rejection. Lab Invest
67:71—79, 1992
141. RUEF C, BUDDE K, LACY J, NORTI-IEMANN W, BAUMAN M, STERZEL
RB, COLEMAN DL: Interleukin 6 is an autocrine growth factor for
mesangial cells. Kidney mt 38:249—257, 1990
142. IKEDA M, IKEDA U, OHARA T, KUSANO E, KANO 5: Recombinant
interleukin-6 inhibits the growth of rat mesangial cells in culture. Am
J Pathol 141:327—334, 1992
143. VANDENBROECKE C, CAILLAT-ZUCMAN 5, LEGENDRE C, NOEL LH,
KREIS H, WooDRow D, BACH JF, TOVEY MG: Differential in situ
expression of cytokines in renal allograft rejection. Transplantation
51:602—609, 1991
144. HANCOCK WH, WHITLEY WD, TULIUS SC, HEEMANN VW, WA-
S0WSKA B, BALDWIN WM, TILNEY NL: Cytokines, adhesion mole-
cules and the pathogenesis of chronic renal allograft rejection.
Transplantation 56:643—650, 1993
145. CLAUSELL N, MoLossl 5, Srr S, RABINOVITCI-I M: In vivo blockade
of tumor necrosis factor-n in cholesterol-fed rabbits after cardiac
transplantation inhibits acute coronary artery neointima! formation.
Circulation 89:2768—2779, 1994
146. RUSSELL PS, CHASE CM, WINN HJ, COLVIN RB: Coronary athero-
sclerosis in transplanted mouse hearts. III Effects of recipient
treatment with a monoclonal antibody to interferon-y. Transplanta-
tion 57:1367—1371, 1994
147. FRITZE LM, REILLY CF, ROSENBERG RD: An antiproliferative
heparan sulfate species produced by post-confluent smooth muscle
cells. J Cell Biol 100:1041—1049, 1985
148. AZIZ 5, TADA Y, GORDON D, MCDONALD TO, FAREED J, VERRIER
ED: A reduction in accelerated graft coronary disease and an
improvement in cardiac allograft survival using low molecular weight
heparin in combination with cyclosporine. J Heart Lung Transplant
12:634—643, 1993
